Author/Authors :
Jahanian Najafabadi, Ali Department of Pharmaceutical Biotechnology - School of Pharmacy - Isfahan University of Medical Sciences, Isfahan, Iran , Mirian, Mina Department of Pharmaceutical Biotechnology - School of Pharmacy - Isfahan University of Medical Sciences, Isfahan, Iran , Rouhani, Fatemeh Department of Pharmaceutical Chemistry - School of Pharmacy - Isfahan University of Medical Sciences, Isfahan, Iran , Karami, Kazem Department of Chemistry - Isfahan University of Technology, Isfahan, Iran , Hosseini Kharat, Mahboubeh Department of Chemistry - Isfahan University of Technology, Isfahan, Iran , Sadeghi Aliabadi, Hojjat Department of Pharmaceutical Chemistry - School of Pharmacy - Isfahan University of Medical Sciences, Isfahan, Iran
Abstract :
Today, development of resistance to anticancer drugs (including cisplatin) is noticed as
a major problem. Recently several studies demonstrated that palladium complexes showed
remarkable cytotoxic effects against K562 cell line and could be used efficiently for treatment
of many human cancers including leukemia. Hereof, K562 cells were made resistant to
cisplatin using increasing concentration of cisplatin up to 4.5 mM and then cytotoxic effect of
synthesized palladium complex was evaluated on this sub-line using MTT assay. Annexin V/
PI staining using flow cytometry and scanning electron microscopy (SEM) were performed to
find out the mechanism of the observed cytotoxicity. Results indicated that tested compounds
had a noticeable cytotoxic effect on K562 cells 80 times more than cisplatin. Palladium
complex also showed significant cytotoxicity on resistant K562 sub-line. Flow cytometry and
SEM results revealed that these compounds exert their cytotoxic effect via apoptosis and it
could be concluded that the novel synthesized palladium complex might be a good candidate
for replacing cisplatin in case of treatment of cisplatin resistant tumors.
Keywords :
Apoptosis assay , MTT assay , Palladacyclic complex , Cisplatin resistance , K562 cells
